18 July. 2018 | PRNewswire
PainReform Ltd, developer of a proprietary reformulation technology, has received FDA approval to conduct two pivotal Phase III clinical trials for post-operative pain relief in soft and hard tissue.
19 June. 2018 | Globes
Israeli drug development company Painreform says it will conduct two Phase III trials of its pain reliever, based on delayed release over 72 hours. The new drug is designed for professional use in hospitals on patients recovering from surgery. Very few pain relievers reach the stage of Phase III trials, the final stage before marketing.